Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls

Pharmacopsychiatry. 1995 May;28(3):80-3. doi: 10.1055/s-2007-979595.

Abstract

Growth-hormone (GH) responses to the alpha 2-adrenoceptor agonist clonidine were measured in 9 panic disorder patients, in 9 patients fulfilling DSM-III-R criteria for major depressive episode, and in 9 age- and sex-matched controls. GH responses to clonidine were not significantly different between the groups. The data do not agree with the assumption that blunted GH responses to clonidine represent a general feature of panic disorder or major depression.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adrenergic alpha-Agonists / adverse effects*
  • Adrenergic alpha-Agonists / therapeutic use
  • Adult
  • Clonidine / adverse effects*
  • Clonidine / therapeutic use
  • Depressive Disorder / blood*
  • Depressive Disorder / drug therapy
  • Depressive Disorder / psychology
  • Female
  • Growth Hormone / blood*
  • Humans
  • Male
  • Middle Aged
  • Panic Disorder / blood*
  • Panic Disorder / drug therapy
  • Panic Disorder / psychology
  • Psychiatric Status Rating Scales

Substances

  • Adrenergic alpha-Agonists
  • Growth Hormone
  • Clonidine